Chris Shibutani
Stock Analyst at Goldman Sachs
(0)
# 4525
Out of 5,298 analysts
110
Total ratings
47.62%
Success rate
-18.95%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PCVX Vaxcyte | Maintains: Buy | 138 100 | 30.48 | 228.08% | 2 | Apr 1, 2025 | |
ERAS Erasca | Maintains: Buy | 4 3 | 1.22 | 145.9% | 7 | Mar 21, 2025 | |
MCRB Seres Therapeutics | Maintains: Sell | 1 1 | 0.68 | 10.29% | 4 | Mar 14, 2025 | |
ALKS Alkermes | Maintains: Strong Buy | 30 32 | 31.66 | 1.07% | 5 | Feb 14, 2025 | |
BNTX BioNTech | Upgrades: Buy | 90 137 | 92.06 | 48.82% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 30 33 | 12.45 | 165.06% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 243 302 | 307.51 | -1.79% | 4 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 50 51 | 31.79 | 60.43% | 3 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 160 155 | 159.99 | -3.12% | 3 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 4 | 3.5 | 14.29% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 9 8 | n/a | n/a | 5 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 18 20 | 14.43 | 38.6% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 650 723 | 788.89 | -8.35% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 29 26 | 18.87 | 37.78% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 134 153 | 102.86 | 48.75% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 173 | 201.29 | -14.05% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 81 69 | 57.69 | 19.6% | 3 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | n/a | n/a | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 13 | 18.07 | -28.06% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 20 23 | 32.89 | -30.07% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 117 144 | n/a | n/a | 2 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 50 | 1.01 | 4850.5% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 40 52 | 23.68 | 119.59% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 47 60 | 24.3 | 146.91% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 18 | 7.99 | 125.28% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 23 20 | n/a | n/a | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 17 | 1.27 | 1238.58% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 90 | n/a | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 3 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Dec 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | May 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Mar 24, 2017 |